JosephJoe LukoseVadakaraMDFACP

Clinical Trials

• Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma Start of enrollment: 2010 Sep 01

  Completed

  Phase 2

• Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24

  Active, not recruiting

  Phase 3

• Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma Start of enrollment: 2012 Sep 01

  Active, not recruiting

  Phase 2

• Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2013 Dec 06

  Active, not recruiting

  Phase 3

• Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19

  Active, not recruiting

  Phase 3

• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Start of enrollment: 2015 Sep 08

  Active, not recruiting

  Phase 3

• Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer Start of enrollment: 2015 Aug 27

  Completed

  Phase 2

• Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2016 Oct 12

  Active, not recruiting

  Phase 3

• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Start of enrollment: 2015 Aug 17

  Active, not recruiting

  Phase 2

• Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Start of enrollment: 2015 Aug 13

  Completed

  Phase 2

• Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Start of enrollment: 2015 Nov 10

  Active, not recruiting

  Phase 3

• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone Start of enrollment: 2015 Dec 01

  Active, not recruiting

  Phase 3

• The National Myelodysplastic Syndromes (MDS) Study Start of enrollment: 2016 Jun 13

  Recruiting

• Join now to see all